Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging (PRSTEC_multipr)
Preoperative Risk Stratification in Endometrial Cancer Using Expert Ultrasound and Molecular Classification for Tailoring Lymph Node Staging: Multicentric Prospective Observational Study
The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:
Is there any group of patients who doesn't need lymph node staging for proper indication of adjuvant treatment? Participants are note taking any intervention. They are treated according to current standard of care and followed 3-years after primary surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Hradec Králové, Czechia
- Recruiting
- University Hospital Hradec Kralove
-
Contact:
- Petra Bretova
- Phone Number: +420777679238
- Email: bretova.petra@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women ≥18 years with newly diagnosed endometrial cancer (any histology)
- Undergoing primary surgical management
- Preoperative expert ultrasound, CT scan (could be waived in low risk cases)
- Preoperatively early-stage (stage I-II) of EC
- SLN mapping attempted intraoperatively
- FFPE tumor tissue available for molecular and IHC testing from biopsy
- Signed informed consent with the participation in the study
Exclusion Criteria:
- Neoadjuvant treatment
- Recurrent or metastatic disease at diagnosis
- Inadequate imaging or tissue samples
- Cancer synchronous duplicity
- Prior oncological treatment within the last five years
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The accuracy of preoperative risk stratification
Time Frame: From enrollment to the first follow-up visit at 4 weeks after surgery.
|
From enrollment to the first follow-up visit at 4 weeks after surgery.
|
|
Determination of specific groups for whom: 1) lymph node staging is crucial for changing risk category and adjuvant treatment decisions, and 2) lymph node staging could be safely omitted
Time Frame: From enrollment to the first follow-up visit at 4 weeks after surgery.
|
From enrollment to the first follow-up visit at 4 weeks after surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202511P08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.